AstraZeneca ROE 2006-2018 | AZN

Current and historical return on equity (ROE) values for AstraZeneca (AZN) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. AstraZeneca ROE for the three months ending June 30, 2018 was 29.89%.
AstraZeneca Annual ROE
2017 17.23
2016 20.43
2015 15.27
2014 6.29
2013 11.06
2012 26.18
2011 42.40
2010 34.52
2009 36.23
2008 38.17
2007 39.88
2006 39.62
2005 34.74
AstraZeneca Quarterly ROE
Q2 2018 2.24
Q1 2018 2.17
Q4 2017 7.58
Q3 2017 4.20
Q2 2017 2.89
Q1 2017 3.46
Q4 2016 10.90
Q3 2016 6.67
Q2 2016 -0.20
Q1 2016 3.76
Q4 2015 4.37
Q3 2015 4.43
Q2 2015 3.80
Q1 2015 3.26
Q4 2014 -1.63
Q3 2014 1.24
Q2 2014 3.61
Q1 2014 2.36
Q4 2013 -2.24
Q3 2013 5.32
Q2 2013 3.55
Q1 2013 4.50
Q4 2012 6.35
Q3 2012 6.83
Q2 2012 7.21
Q1 2012 7.49
Q4 2011 6.36
Q3 2011 14.43
Q2 2011 8.92
Q1 2011 12.93
Q4 2010 6.97
Q3 2010 6.97
Q2 2010 9.50
Q1 2010 13.30
Q4 2009 7.50
Q3 2009 10.82
Q2 2009 9.51
Q1 2009 13.81
Q4 2008 7.78
Q3 2008 10.79
Q2 2008 10.14
Q1 2008 10.22
Q4 2007 8.66
Q3 2007 0.00
Q2 2007 9.43
Q1 2007 11.25
Q4 2006 9.44
Q3 2006 10.84
Q2 2006 10.75
Q1 2006 10.46
Q4 2005 9.02
Q3 2005 9.27
Q2 2005 9.05
Q1 2005 7.67
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $94.477B $22.465B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $376.840B 18.01
Pfizer (PFE) United States $257.521B 15.07
Novartis AG (NVS) Switzerland $196.752B 16.88
Merck (MRK) United States $188.679B 16.66
AbbVie (ABBV) United States $137.829B 13.46
Novo Nordisk (NVO) Denmark $114.846B 18.36
Eli Lilly (LLY) United States $113.563B 21.02
Sanofi (SNY) France $110.105B 13.94
Bristol-Myers Squibb (BMY) United States $99.380B 17.99
GlaxoSmithKline (GSK) United Kingdom $98.081B 13.10